Stay updated with breaking news from Nasdaq Carm. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Carisma Therapeutics, Inc. (NASDAQ:CARM – Get Rating) saw a significant decline in short interest in May. As of May 31st, there was short interest totalling 521,900 shares, a decline of 18.1% from the May 15th total of 636,900 shares. Approximately 3.2% of the shares of the stock are short sold. Based on an average daily […]
Carisma Therapeutics (NASDAQ:CARM – Get Rating) is one of 997 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its rivals? We will compare Carisma Therapeutics to related businesses based on the strength of its earnings, analyst recommendations, profitability, risk, institutional ownership, valuation and dividends. Earnings & Valuation This […]
Carisma Therapeutics (NASDAQ:CARM – Get Rating) was upgraded by stock analysts at Jefferies Financial Group from a “hold” rating to a “buy” rating in a note issued to investors on Wednesday, Marketbeat reports. The brokerage presently has a $7.00 price objective on the stock. Jefferies Financial Group’s price target would indicate a potential upside of […]
HC Wainwright reissued their buy rating on shares of Carisma Therapeutics (NASDAQ:CARM – Get Rating) in a research note released on Wednesday morning, Marketbeat.com reports. They currently have a $10.00 target price on the stock. HC Wainwright also issued estimates for Carisma Therapeutics’ Q2 2023 earnings at ($0.66) EPS, Q3 2023 earnings at ($0.71) EPS, […]
Carisma Therapeutics (NASDAQ:CARM – Get Rating) and Synaptogenix (NASDAQ:SNPX – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, valuation, earnings, analyst recommendations, institutional ownership and profitability. Valuation & Earnings This table compares Carisma Therapeutics and Synaptogenix’s […]